Veloxis Pharmaceuticals A/S (VELO.CO)

Copenhagen - Copenhagen Delayed Price. Currency in DKK
1.25-0.02 (-1.57%)
As of 9:50 AM EDT. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close1.27
Bid1.25 x
Ask1.26 x
Day's Range1.25 - 1.28
52wk Range0.93 - 2.10
1y Target EstN/A
Market Cap2.13B
P/E Ratio (ttm)-62.50
Avg Vol (3m)1,356,705
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • PR Newswire11 months ago

    Veloxis Announces Change In Management

    "Bill has been instrumental in bringing the company successfully through its development phase with regulatory approval of Envarsus® in both Europe and the US and we thank him for his dedicated contribution," said Mette Kirstine Agger, Chairman of the Board of Veloxis. Earlier this week, Veloxis announced the launch of Envarsus XR in the US and is transitioning from a development company into a commercial company. Dr. Polvino will be followed by Craig A. Collard who will take over the position as President and CEO with immediate effect.

  • PR Newswire11 months ago

    Veloxis Launches Envarsus®XR for Treatment of Kidney Transplant Patients in U.S.

    HORSHOLM, Denmark, Dec. 7, 2015 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the U.S. launch of Envarsus ® XR (tacrolimus extended-release tablets) for the prophylaxis of rejection ...

  • PR Newswire11 months ago

    Veloxis Pharmaceuticals announces financial results for the first nine months of 2015

    HORSHOLM, Denmark, Nov. 11, 2015 /PRNewswire/ -- Highlights: On 30 September, 2015, Veloxis had cash and cash equivalents of DKK 157.6 million, and the Company's cash position is expected to be in the ...